Khoa Dang P. Nguyen

Khoa Dang P. Nguyen

Auto-generated profile, based on publicly available information

Khoa Dang P. Nguyen

Thoracic and GI Malignancies Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2021 in Cancer Research
Verified
Journal Article
Open access
PDF file
XZXu Zhang
Xu Zhang
TMTapan K. Maity
Tapan K. Maity
KRKaren E. Ross
Karen E. Ross
YQYue Qi
Yue Qi
CCConstance M. Cultraro
Constance M. Cultraro
UGUdayan Guha
Udayan Guha
Lung cancer is the leading cause of cancer mortality worldwide. The treatment of patients with lung cancer harboring mutant EGFR with orally administered EGFR tyrosine kinase inhibitors (TKI) has been a paradigm shift. Osimertinib and rociletinib are third-generation irreversible EGFR TKIs targeting the EGFR T790M mutation. Osimertinib is the current standard of care for patients with EGFR mutations due to increased efficacy, lower side effects, and enhanced brain penetrance. Unfortunately, all patients develop resistance. Genomic approaches have primarily been used to interrogate resistance mechanisms. Here we characterized the proteome and phosphoproteome of a series of isogenic EGFR-mutant lung adenocarcinoma cell lines that are either sensitive or resistant to these drugs, comprising the most comprehensive proteomic dataset resource to date to investigate third generation EGFR TKI resistance in lung adenocarcinoma. Unbiased global quantitative mass spectrometry uncovered alterations in signaling pathways, revealed a proteomic signature of epithelial–mesenchymal transition, and identified kinases and phosphatases with altered expression and phosphorylation in TKI-resistant cells. Decreased tyrosine phosphorylation of key sites in the phosphatase SHP2 suggests its inhibition, resulting in subsequent inhibition of RAS/MAPK and activation of PI3K/AKT pathways. Anticorrelation analyses of this phosphoproteomic dataset with published drug-induced P100 phosphoproteomic datasets from the Library of Integrated Network-Based Cellular Signatures program predicted drugs with the potential to overcome EGFR TKI resistance. The PI3K/MTOR inhibitor dactolisib in combination with osimertinib overcame resistance both in vitro and in vivo. Taken together, this study reveals global proteomic alterations upon third generation EGFR TKI resistance and highlights potential novel approaches to overcome resistance. Significance: Global quantitative proteomics reveals changes in the proteome and phosphoproteome in lung cancer cells resistant to third generation EGFR TKIs, identifying the PI3K/mTOR inhibitor dactolisib as a potential approach to overcome resistance.

1 April 2019 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
PDF file
XZXu Zhang
Xu Zhang
KNKhoa Dang Nguyen
Khoa Dang Nguyen
PRPaul A. Rudnick
Paul A. Rudnick
NRNitin Roper
Nitin Roper
EKEmily Kawaler
Emily Kawaler
UGUdayan Guha
Udayan Guha
Lung cancer is the leading cause of cancer death in both men and women. Tumor heterogeneity is an impediment to targeted treatment of all cancers, including lung cancer. Here, we sought to characterize tumor proteome and phosphoproteome changes by longitudinal, prospective collection of tumor tissue from an exceptional responder lung adenocarcinoma patient who survived with metastatic lung adenocarcinoma for over seven years while undergoing HER2-directed therapy in combination with chemotherapy. We employed “Super-SILAC” and TMT labeling strategies to quantify the proteome and phosphoproteome of a lung metastatic site and eight distinct metastatic progressive lymph nodes collected during these seven years, including five lymph nodes procured at autopsy. We identified specific signaling networks enriched in lung in comparison to the lymph node metastatic sites. We correlated the changes in protein abundance with changes in copy number alteration (CNA) and transcript expression. ERBB2/HER2 protein expression was higher in lung, consistent with a higher degree of ERBB2 amplification in lung compared to the lymph node metastatic sites. To further interrogate the mass spectrometry data, a patient-specific database was built by incorporating all the somatic and germline variants identified by whole genome sequencing (WGS) of genomic DNA from the lung, one lymph node metastatic site and blood. An extensive validation pipeline was built to confirm variant peptides. We validated 360 spectra corresponding to 55 germline and 6 somatic variant peptides. Targeted MRM assays revealed two novel variant somatic peptides, CDK12-G879V and FASN-R1439Q, expressed in lung and lymph node metastatic sites, respectively. The CDK12-G879V mutation likely results in a nonfunctional CDK12 kinase and chemotherapy susceptibility in lung metastatic sites. Knockdown of CDK12 in lung adenocarcinoma cells increased chemotherapy sensitivity which was rescued by wild type, but not CDK12-G879V expression, consistent with the complete resolution of the lung metastatic sites in this patient.

13 April 2021 in Oncogene
Verified
Journal Article
Closed access
PDF file
AVAbhilash Venugopalan
Abhilash Venugopalan
MLMatthew Lynberg
Matthew Lynberg
CCConstance M. Cultraro
Constance M. Cultraro
KNKhoa Dang P. Nguyen
Khoa Dang P. Nguyen
XZXu Zhang
Xu Zhang
UGUdayan Guha
Udayan Guha

29 September 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
SNSuchitra Natarajan
Suchitra Natarajan
KNKhoa Nguyen
Khoa Nguyen
HLHeyuan Li
Heyuan Li
ESElysia Saputra
Elysia Saputra
CLCindy Li
Cindy Li
XYXin Yu
Xin Yu
Cancer-associated fibroblasts (CAF) are key components of the tumor microenvironment (TME) that promote tumor progression either directly through tumor–CAF interactions or indirectly by influencing tumor-infiltrating immune cells, thereby creating an immunosuppressive TME. High stromal signatures have been associated with reduced therapeutic efficacy and resistance to immune checkpoint blockades. Adipocyte enhancer–binding protein 1 (AEBP1) is predominantly expressed in myofibroblasts, and its expression is further increased in CAFs that produce the extracellular matrix. It has two isoforms: The extracellular isoform binds to collagen and promotes collagen remodeling, whereas the intracellular isoform modulates transcription and signaling. We observed the expression of both isoforms in primary human CAFs. Our data showed that the combined knockout (KO) of both AEBP1 isoforms via gene editing decreased CAF proliferation, collagen gel contractility, and CAF-mediated tumor cell proliferation in vitro. AEBP1 KO mouse fibroblasts demonstrated reduced activity in both in vitro assays and in vivo within a coimplantation mouse model. RNA sequencing revealed that AEBP1 KO downregulated the collagen biosynthesis and extracellular matrix organization–related pathways in mouse fibroblasts and human CAFs. Importantly, AEBP1 loss in fibroblasts led to significant alterations in tumor cell phenotypes, including a marked reduction of tumor cells exhibiting an epithelial–mesenchymal transition signature in vivo. Furthermore, AEBP1 KO in CAFs enhanced the anti-PD-1–induced effector T-cell function and the anti–PD-1 efficacy. Our findings indicate that AEBP1 plays a crucial role in regulating the function of CAFs within the TME. Targeting AEBP1 could be a promising strategy to inhibit the tumor-promoting activities of CAFs and to overcome resistance to anti–PD-1 immunotherapy.

31 March 2023
Verified
Other
Open access
XZXu Zhang
Xu Zhang
TMTapan K. Maity
Tapan K. Maity
KRKaren E. Ross
Karen E. Ross
YQYue Qi
Yue Qi
CCConstance M. Cultraro
Constance M. Cultraro
UGUdayan Guha
Udayan Guha

31 March 2023
Verified
Other
Open access
XZXu Zhang
Xu Zhang
TMTapan K. Maity
Tapan K. Maity
KRKaren E. Ross
Karen E. Ross
YQYue Qi
Yue Qi
CCConstance M. Cultraro
Constance M. Cultraro
UGUdayan Guha
Udayan Guha